Study of genetics, orforglipron, and diabetes medication response
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how your genes affect your response to a diabetes medication called orforglipron. You will stop your usual diabetes pills for 5 days, then take the study drug and have a meal test to see how your blood sugar and body respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You take 2 or fewer diabetes pills (or none at all). You are not on insulin or injectable diabetes medications.
- You can stop your diabetes pills for 5 days before the study starts, with your doctor's approval.
- Your most recent A1C is below 7.5%. Your average blood sugar in the last 3 months is under 180 mg/dL.
- You do not have a history of pancreatitis, gallbladder problems, or certain stomach conditions.
- You do not have a personal or family history of medullary thyroid cancer (a rare type of thyroid cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called orforglipron to see if it safely helps people with type 2 diabetes manage their blood sugar while they fast during Ramadan. You may be a good fit if you are planning to fast and your diabetes is not too severe.
This trial tests an experimental medication that may help with weight loss. It aims to see how safe the drug is and how the body responds, possibly leading to a new treatment option for obesity.
This trial tests an investigational oral medication to help Chinese adults with overweight or obesity, plus related health issues, lose weight. It focuses on improving weight loss and overall health in this group.
This study looks at how your genes affect your body's response to a diabetes medication called semaglutide. It may help people with slightly high blood sugar (pre-diabetes) understand why some respond better than others.
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
This study tests a new daily pill, orforglipron, compared to another injectable medicine (dulaglutide) in children and teens with type 2 diabetes. It aims to see if the new pill can improve blood sugar control with fewer injections.
Hear when a new Pharmacogenomic Drug Interaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.